
|Articles|February 16, 2021
Raremark Rebrands as Xperiome
Advertisement
Raremark has announced that it is rebranding as Xperiome. Jeremy Edwards, CEO of Xperiome, commented, “Strategically, we are rebranding because we have two very different audiences, with individual needs that will benefit from equal attention and focus.”
Xperiome will now become the name and corporate identity of the company, while the Raremark brand will solely represent its patient-facing activities dedicated to helping people better understand, talk about and manage rare diseases.
For more information, click
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Real-Time Evidence Generation, Protocol Digitization, and Decentralized Trial Flexibility
2
2026 DIA Global Annual Meeting: Stacy Hurt of Parexel on Federated AI, the Patient Voice, and Accountability for Patient Needs
3
ACT Brief: Mixed FSP Strategy, DIA Meeting Trends, and Patient Voice in Oncology
4
ICON Selects Microsoft as Preferred Technology Partner to Scale Agentic AI Platform Across Clinical Trial Lifecycle
5




